Last Updated: May 11, 2026

Claims for Patent: 12,156,865


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 12,156,865
Title:Formulation for soft anticholinergic analogs
Abstract:Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.
Inventor(s):Nicholas S. Bodor, John J. Koleng, David Angulo
Assignee: Bodor Laboratories Inc
Application Number:US17/479,905
Patent Claims: 1. A topical composition for administration to skin, comprising the following ingredients: (a) a compound having the formula: said compound having the R stereoisomeric configuration at the 2 position and the R, S or RS stereoisomeric configuration at the 1′ and 3′ positions, or being a mixture thereof; (b) anhydrous ethanol; and (c) isopropyl myristate; wherein the compound of formula (2) is present in the composition in an anticholinergic effective amount; provided that said topical composition is anhydrous and comprises from about 1% to about 25% w/w of the compound of formula (2), said composition having greater storage stability after 7 days at 40° C. compared to a composition comprising an aqueous solvent or aqueous buffer, with the proviso that said ingredients are present in amounts such that the product of any transesterification is the same as the compound of formula (2), and with the proviso that said anhydrous ethanol is present in an amount sufficient to act as a non-aqueous solvent for the compound of formula (2).

2. The composition of claim 1, wherein the composition is formulated as a gel, cream, lotion, foam, patch, wipe, or emulsion.

3. The composition of claim 1, wherein the composition is formulated as a gel, cream, lotion, foam, or emulsion.

4. The composition of claim 1, wherein the composition is a topical anhydrous gel composition.

5. The composition of claim 1, comprising at least about 70% w/w anhydrous ethanol.

6. The composition of claim 1, comprising from about 70% to about 99.99% w/w anhydrous ethanol.

7. The composition of claim 1, comprising from about 70% to about 85% w/w anhydrous ethanol.

8. The composition of claim 1, wherein the compound of formula (2) is selected from the group consisting of: (ii) (2R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide; (iii) (2R,3′R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide; (iv) (2R,3′S) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide; (v) (2R, 1′R,3′S) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide; (vi) (2R, 1′S,3′S) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide; (vii) (2R, 1′R,3′R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide; and (viii) (2R, 1′S,3′R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide.

9. The composition of claim 1, wherein the compound of formula (2) is (2R, 3′R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide.

10. The composition of claim 1, wherein the compound of formula (2) is at a concentration of from about 1% w/v or w/w to about 20% w/v or w/w of the composition.

11. The composition of claim 10, wherein the compound of formula (2) is at a concentration of from about 2% w/v or w/w to about 10% w/v or w/w of the composition.

12. The composition of claim 1, further comprising citric acid.

13. The composition of claim 1, further comprising hexylene glycol.

14. The composition of claim 1, further comprising citric acid and hexylene glycol.

15. The composition of claim 14, wherein the composition is a topical anhydrous gel composition.

16. A method of treating hyperhidrosis in a subject, said method comprising topically administering a composition as claimed in claim 1 to skin of an area of a subject suffering from hyperhidrosis.

17. The method of claim 16, wherein the compound is delivered to sweat glands in the skin of an anatomic area selected from a hand palm area, a foot plantar area, a groin area, an axilla area, and a facial area of the subject.

18. The method of claim 16, wherein: (a) the composition is a topical anhydrous gel composition; (b) the composition comprises at least about 70% w/w anhydrous ethanol; and (c) the composition comprises at least one gelling or viscosity-controlling ingredient.

19. The method of claim 18, wherein the compound is delivered to sweat glands in the skin of an anatomic area selected from a hand palm area, a foot plantar area, a groin area, an axilla area, and a facial area of the subject.

20. The method of claim 16, wherein said composition is a topical anhydrous gel composition comprising citric acid, hexylene glycol and at least one gelling or viscosity-controlling ingredient.

21. The method of claim 20, wherein the compound is delivered to sweat glands in the skin of an anatomic area selected from a hand palm area, a foot plantar area, a groin area, an axilla area, and a facial area of the subject.

22. The method of claim 21, wherein the gelling or viscosity-controlling ingredient comprises hydroxypropyl cellulose.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.